GHK-Cu typical research dosing
Across the available literature, GHK-Cu is most commonly administered at 1000–2000 mcg per dose, 1 time(s) per day, via subcutaneous injection. GHK-Cu is most commonly studied topically. Injectable research protocols typically use 1–2 mg subcutaneously per administration.
GHK-Cu unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 50 mg GHK-Cu vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 1000 mcg | 1500 mcg | 2000 mcg |
|---|---|---|---|---|
| 1 mL | 50000 mcg/mL | 2.0 units | 3.0 units | 4.0 units |
| 2 mL | 25000 mcg/mL | 4.0 units | 6.0 units | 8.0 units |
| 3 mL | 16667 mcg/mL | 6.0 units | 9.0 units | 12.0 units |
| 5 mL | 10000 mcg/mL | 10.0 units | 15.0 units | 20.0 units |
GHK-Cu cycle length
Most reported GHK-Cu protocols run 8 weeks on, then 4 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
GHK-Cu half-life and timing
GHK-Cu has a half-life of approximately 4 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.